[多学科的护理和治疗的进步在肌缩侧面硬化症]
José Manuel Matamala1, Javier Moreno-Roco1, Ignacio Acosta1
1Laboratorio de Neurología y Neurofisiología Traslacional, Facultad de Medicina, Universidad de Chile, Santiago, Chile.
概括
肌缩性侧面硬化症 (ALS) 管理侧重于通过多学科护理,营养支持和新疗法来改善生活质量和延长生存时间. 早期的息治疗和预期指导方针对于解决患者病情恶化和各种症状至关重要.
科学领域:
- 神经学 神经学
- 神经退行性疾病 神经退行性疾病
背景情况:
- 肌缩侧面硬化症 (ALS) 是一种进展性神经退行性疾病,影响运动系统,导致肌肉疲软和衰竭.
- 目前,ALS尚无治愈方法,由于症状多样化和进展,使其管理变得复杂.
研究的目的:
- 更新当前治疗策略,以管理肌缩侧面硬化症 (ALS).
- 审查不断发展的临床试验和ALS治疗的新疗法.
主要方法:
- 审查当前针对ALS患者的多学科护理方法.
- 支持性干预措施的分析,包括营养,代谢和呼吸管理.
- 评估新兴的疾病修饰疗法和临床试验.
主要成果:
- 多学科护理,呼吸管理和疾病修饰疗法改善了ALS患者的生活质量和生存率.
- 营养支持对于维持体重至关重要.
- 对神经精神病症状的管理和沟通的维护至关重要.
结论:
- 通过早期息治疗优化症状管理对于ALS患者至关重要.
- 需要预期的指导方针,以准备患者的病情恶化.
- 正在进行的新疗法研究为改善ALS治疗结果提供了希望.
相关概念视频
Parkinson's Disease: Treatment
281
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
281
Alzheimer's Disease: Treatment
197
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
197
Parkinson's Disease: Overview
564
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
564
Myasthenia Gravis: Overview and Treatment
1.5K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.5K
Peripheral Artery Disease III: Interprofessional Care
11
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
11
Drug Therapy
47
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
47


